The effectiveness of gefitinib on spinal metastases of lung cancer - report of two cases -.
Lung cancer has a high mortality rate and is often diagnosed at the metastatic stage. Recently, gefitinib, a molecule target therapeutic drug, has offered a new approach for patients with non-small-cell lung cancer (NSCLC). This report describes the effects of gefitinib on bone metastases in two patients with NSCLC. The pain induced by a bone metastasis was relieved after the administration of gefitinib. Furthermore, the radiographs and CT findings showed sclerotic changes that matched those of the metastatic bone tumor after gefitinib administration in both patients. It is believed that gefitinib inhibited tumor cell proliferation and induced normal bone formation. In patients with NSCLC, gefitinib may be effective in the treatment of bone metastases.
Zukawa
Mineyuki
M
Department of Orthopedic Surgery, University of Toyama, Faculty of Medicine, Toyama, Japan.
Nakano
Masato
M
Hirano
Norikazu
N
Mizuhashi
Keiichi
K
Kanamori
Masahiko
M
Endocr Relat Cancer. 2005 Jun;12(2):471-82
15947117
Spine (Phila Pa 1976). 1990 Nov;15(11):1110-3
1702559
Lung Cancer. 2007 Sep;57(3):359-64
17434236
Gan To Kagaku Ryoho. 2006 Aug;33(8):1049-53
16912519
Oncol Rep. 2005 Dec;14(6):1539-42
16273252
Spine (Phila Pa 1976). 2001 Feb 1;26(3):298-306
11224867
Semin Oncol. 2005 Dec;32(6 Suppl 10):S3-8
16459173
Endocr Relat Cancer. 2006 Mar;13(1):3-6
16601275